bluebird bio, Inc. (BLUE)
$
4.88
+0.80 (16.39%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The financial data pertains to the fiscal year 2023 showcasing the company's operational metrics. The earnings per share (EPS) is reported at -$1.93 indicating the company's profitability on a per-share basis. The diluted EPS is -$1.93 accounting for potential share dilution. The company achieved a revenue of $29,497,000.00 indicating its niche market focus. Furthermore, the cost of revenue for the company is $33,527,000.00 showcasing its production and operational expenses. These figures reflect bluebird bio, Inc.'s ongoing commitment to advancing its innovative gene therapies for severe genetic diseases. With a market capitalization of $47,535,543.00 the company is classified as a small-cap player, making it a notable entity in the biotechnology field. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. The stock is affordable at $5.11 suitable for budget-conscious investors. However, the stock has a low average trading volume of 413,340.00 indicating lower market activity. Moreover, it belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical sector as it continues to develop transformative therapies.
Is bluebird bio, Inc. (BLUE) a good investment?
Investing in bluebird bio, Inc. (BLUE) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is bluebird bio, Inc. (BLUE)'s stock forecast?
Analysts predict bluebird bio, Inc. stock to fluctuate between $3.56 (low) and $28.60 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is bluebird bio, Inc.'s market capitalization?
As of 2025-04-02, bluebird bio, Inc.'s market cap is $47,535,543, based on 9,740,890 outstanding shares.
How does bluebird bio, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., bluebird bio, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy bluebird bio, Inc. (BLUE) stock?
To buy bluebird bio, Inc. (BLUE) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BLUE. Place an order (Market, Limit, etc.).
What is the best time to invest in bluebird bio, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has bluebird bio, Inc. stock ever split?
bluebird bio, Inc.'s last stock split was 1:20 on 2024-12-13.
How did bluebird bio, Inc. perform in the last earnings report?
Revenue: $29,497,000 | EPS: -$1.93 | Growth: -43.07%.
Where can I find bluebird bio, Inc.'s investor relations reports?
Visit https://www.bluebirdbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for bluebird bio, Inc.?
You can explore historical data from here
What is the all-time high and low for bluebird bio, Inc. stock?
All-time high: $978.40 (2021-02-08) | All-time low: $3.56 (2025-02-24).
What are the key trends affecting bluebird bio, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
benzinga.com
Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.
reuters.com
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
marketwatch.com
Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.
businesswire.com
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone. As previously announced on February 21, 2025, bluebird entered into a definitive agreement (the “Merger Agreement”.
zacks.com
Bluebird Bio (BLUE) came out with a quarterly loss of $23.74 per share versus the Zacks Consensus Estimate of a loss of $6.60. This compares to loss of $15.60 per share a year ago.
prnewswire.com
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
accessnewswire.com
PHILADELPHIA, PA / ACCESS Newswire / March 12, 2025 / Kehoe Law Firm, P.C. continues its investigation on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives.
prnewswire.com
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
See all news
